Effects of addition of low-dose oral daily prednisolone to the initial disease-modifying anti-rheumatic drugs (DMARD) therapy on progression of radiographic damage and disease activity in patients with early rheumatoid arthritis, as well as effects on adverse outcomes and toxicity

Karolinska Institute (Karolinska Institutet) (Sweden)0 个研究点目标入组 250 人开始时间: 2014年2月4日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Diagnosis of RA according to the 1987 revised criteria of the American College of Rheumatology (ACR)
•2. Age 18-80 years
•3. Disease duration of = 1 year
•4. Active disease defined as a Disease Activity Score in 28 joints (DAS28) of >3.0
•5. Started by the treating rheumatologist on the first DMARD

•1. Earlier treatment with glucocorticoids for RA or other diseases
•2. Previous treatment with DMARDs
•3. Contraindication for glucocorticoid therapy
•4. Previous fragility fractures
•5. Patients aged < 65 years with a T-score lower than -2.5 on bone densitometry; and patients aged = 65 years with a Z-score of less than -1

发起方

Karolinska Institute (Karolinska Institutet) (Sweden)